Response to IL-6 of HPV-18 cervical carcinoma cell lines

Virology. 1999 Jun 5;258(2):344-54. doi: 10.1006/viro.1999.9722.

Abstract

The human papillomavirus type 18 (HPV-18) upstream regulatory region (URR) controls cell type-specific expression of the viral oncoproteins E6 and E7. The HPV-18 URR is active in the cervical carcinoma cell line HeLa but inactive in the hepatoma cell line HepG2. C/EBPss (NF-IL-6) was shown to participate as an important regulator in HPV transcription dependent on the cell type. The finding that C/EPBss is critical for HPV-18 URR activity and that C/EPBss is induced by IL-6 offers the opportunity of manipulating HPV activity by specific cytokine treatment. In this report, we show that treatment with IL-6 results in activation of HPV-18 URR activity in HepG2 cells. In contrast, the HPV-18 URR is not inducible by IL-6 in three cervical carcinoma cell lines. In all three cell lines we found decreased expression of the IL-6 receptor compared to the IL-6-responsive HepG2 cells, whereas the level of expression of the signal transduction component gp130 is present in all cells. These results suggest that cervical carcinoma cells may circumvent the IL-6-induced cellular defense mechanism through downregulation of the IL-6-receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / genetics
  • Cytokine Receptor gp130
  • Female
  • Gene Expression Regulation, Viral / drug effects
  • HeLa Cells
  • Humans
  • Interleukin-6 / immunology*
  • Interleukin-6 / pharmacology
  • Membrane Glycoproteins / genetics
  • Papillomaviridae / genetics
  • Papillomaviridae / immunology*
  • Receptors, Interleukin-6 / genetics
  • Tumor Cells, Cultured
  • Uterine Cervical Neoplasms / immunology*
  • Uterine Cervical Neoplasms / virology*

Substances

  • Antigens, CD
  • IL6ST protein, human
  • Interleukin-6
  • Membrane Glycoproteins
  • Receptors, Interleukin-6
  • Cytokine Receptor gp130